Table 1 Patients’ characteristics in the TS and VS (overall population, N=1104)

From: Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer

 

TS

N(%)

VS

N(%)

P-value

Number of patients

596 (100)

508 (100)

Gender

Male

359 (60.2)

318 (62.6)

0.46

Female

237 (39.8)

190 (37.4)

 

Age (years)

<65

287 (48.2)

224 (44.1)

0.20

65

309 (51.8)

284 (55.9)

 

ECOG-PS

0–1

468 (78.5)

433 (85.2)

<0.0001

2

10 (1.7)

75 (14.8)

 

Missing

118 (19.8)

0 (0)

 

Driver mutation

Wt

227 (38.1)

213 (41.8)

0.96

BRAF mutant (V600E)

54 (9.1)

49 (9.6)

 

RAS mutant

315 (52.8)

246 (48.6)

 

Number of metastatic sites

1

378 (63.4)

216 (42.5)

<0.0001

>1

218 (36.6)

292 (57.5)

 

Peritoneal metastases

Yes

130 (21.8)

107 (21.1)

0.82

No

466 (78.2)

401 (78.9)

 

Lung metastases

Yes

147 (24.7)

152 (29.9)

0.06

No

449 (75.3)

356 (70.1)

 

Synchronous metastases

Yes

412 (69.1)

367 (72.2)

0.29

No

184 (30.9)

141 (27.8)

 

Distant lymph-node metastases

Yes

117 (19.6)

110 (21.7)

0.45

No

479 (80.4)

398 (78.3)

 

Mucinous histology

Yes

110 (18.5)

76 (15.0)

<0.0001

No

395 (66.3)

416 (81.9)

 

Missing

91 (15.3)

16 (3.1)

 

Primary tumour site

Right

202 (33.9)

162 (31.9)

0.52

Left

394 (66.1)

346 (68.1)

 

Primary tumour resected

Yes

466 (78.2)

344 (67.8)

<0.0001

No

130 (21.8)

164 (32.2)

 

Tumour grading

G1–2

248 (41.6)

143 (28.1)

<0.0001

G3–4

195 (32.7)

221 (43.5)

 

Missing

153 (25.7)

144 (28.3)

 
  1. Abbreviations: N=number; PS=performance status; TS=training set; VS=validation set; wt=wild type.
  2. %: rate; P-value: χ2 test.